Novartis India Limited (BOM:500672)
785.55
+19.15 (2.50%)
At close: Jan 22, 2026
Novartis India Revenue
Novartis India had revenue of 903.30M INR in the quarter ending September 30, 2025, with 3.71% growth. This brings the company's revenue in the last twelve months to 3.55B, up 2.80% year-over-year. In the fiscal year ending March 31, 2025, Novartis India had annual revenue of 3.56B with 6.33% growth.
Revenue (ttm)
3.55B
Revenue Growth
+2.80%
P/S Ratio
5.47
Revenue / Employee
63.35M
Employees
56
Market Cap
19.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.56B | 212.00M | 6.33% |
| Mar 31, 2024 | 3.35B | -436.70M | -11.53% |
| Mar 31, 2023 | 3.79B | -211.30M | -5.28% |
| Mar 31, 2022 | 4.00B | 185.20M | 4.86% |
| Mar 31, 2021 | 3.81B | -569.00M | -12.98% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 22.26B |
| Morepen Laboratories | 17.56B |
| Hikal | 16.99B |
| Gufic Biosciences | 8.74B |
| Bliss GVS Pharma | 8.60B |
| TTK Healthcare | 8.25B |
| Venus Remedies | 6.99B |
| Syncom Formulations (India) | 5.15B |
Novartis India News
- 1 year ago - Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition - Business Upturn